Oleg F. Sharifov

Oleg F. Sharifov

Auto-generated profile, based on publicly available information

Oleg F. Sharifov

University of Alabama at Birmingham

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2020 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
SASudeep R. Aryal
Sudeep R. Aryal
OSOleg F. Sharifov
Oleg F. Sharifov
SLSteven G. Lloyd
Steven G. Lloyd
Pulmonary hypertension (PH) is a clinical condition characterised by elevation of pulmonary arterial pressure (PAP) above normal range due to various aetiologies. While cardiac right-heart catheterisation (RHC) remains the gold standard and mandatory for establishing the diagnosis of PH, noninvasive imaging of the heart plays a central role in the diagnosis and management of all forms of PH. Although Doppler echocardiography (ECHO) can measure a range of haemodynamic and anatomical variables, it has limited utility for visualisation of the pulmonary artery and, oftentimes, the right ventricle. Cardiovascular magnetic resonance (CMR) provides comprehensive information about the anatomical and functional aspects of the pulmonary artery and right ventricle that are of prognostic significance for assessment of long-term outcomes in disease progression. CMR is suited for serial follow-up of patients with PH due to its noninvasive nature, high sensitivity to changes in anatomical and functional parameters, and high reproducibility. In recent years, there has been growing interest in the use of CMR derived parameters as surrogate endpoints for early-phase PH clinical trials. This review will discuss the role of CMR in the diagnosis and management of PH, including current applications and future developments, in comparison to other existing major imaging modalities.

1 October 2011 in European Journal of Pharmacology
Verified
Journal Article
Closed access
PWPaul E. Wolkowicz
Paul E. Wolkowicz
JHJian Huang
Jian Huang
PUPatrick K. Umeda
Patrick K. Umeda
OSOleg F. Sharifov
Oleg F. Sharifov
ETEdlue Tabengwa
Edlue Tabengwa
HGHernan E. Grenett
Hernan E. Grenett

7 September 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SASudeep R. Aryal
Sudeep R. Aryal
MSMohammed Siddiqui
Mohammed Siddiqui
OSOleg F. Sharifov
Oleg F. Sharifov
MCMegan D. Coffin
Megan D. Coffin
BZBin Zhang
Bin Zhang
SLSteven G. Lloyd
Steven G. Lloyd
Background: Aortic stiffness is an independent predictor of cardiovascular events in patients with arterial hypertension. Resistant hypertension is often linked to hyperaldosteronism and associated with adverse outcomes. Spironolactone, a mineralocorticoid receptor antagonist, has been shown to reduce both the arterial blood pressure (BP) and aortic stiffness in resistant hypertension. However, the mechanism of aortic stiffness reduction by spironolactone is not well understood. We hypothesized that spironolactone reduces aortic stiffness in resistant hypertension independently of BP change. Methods and Results: Patients with uncontrolled BP (≥140/90 mm Hg) despite use of ≥3 antihypertensive medications (including diuretics) were prospectively recruited. Participants were started on spironolactone at 25 mg/d, and increased to 50 mg/d at 4 weeks while other antihypertensive medications were withdrawn to maintain constant mean BP. Phase‐contrast cardiac magnetic resonance imaging of the ascending aorta was performed in 30 participants at baseline and after 6 months of spironolactone treatment to measure aortic pulsatility, distensibility, and pulse wave velocity. Pulse wave velocity decreased (6.3±2.3 m/s to 4.5±1.8 m/s, P <0.001) and pulsatility and distensibility increased (15.9%±5.3% to 22.1%±7.9%, P <0.001; and 0.28%±0.10%/mm Hg to 0.40%±0.14%/mm Hg, P <0.001, respectively) following 6 months of spironolactone. Conclusions: Our results suggest that spironolactone improves aortic properties in resistant hypertension independently of BP, which may support the hypothesis of an effect of aldosterone on the arterial wall. A larger prospective study is needed to confirm our findings.

29 May 2023 in International Journal of Cardiology
Verified
Journal Article
Closed access
OSOleg F. Sharifov
Oleg F. Sharifov
TDThomas Denney
Thomas Denney
AGAndrew A. Girard
Andrew A. Girard
HGHimanshu Gupta
Himanshu Gupta
SLSteven G. Lloyd
Steven G. Lloyd

20 December 2023 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
AGAndrew A. Girard
Andrew A. Girard
TDThomas S. Denney
Thomas S. Denney
HGHimanshu Gupta
Himanshu Gupta
LDLouis J. Dell’iTalia
Louis J. Dell’iTalia
DCDavid A. Calhoun
David A. Calhoun
SLSteven G. Lloyd
Steven G. Lloyd

27 March 2023 in Cardiovascular Engineering and Technology
Verified
Journal Article
Closed access
PDF file
MAM. Rifqi Aufan
M. Rifqi Aufan
ZJZachary T. Jost
Zachary T. Jost
NMNeal J. Miller
Neal J. Miller
OSOleg F. Sharifov
Oleg F. Sharifov
HGHimanshu Gupta
Himanshu Gupta
SLSteven G. Lloyd
Steven G. Lloyd